[From this newspaper]After the 2003 SARS outbreak, Hong Kong people snapped up Chinese patent medicines to protect themselves in the fifth wave of COVID-19. “Lianhua Qingwen Capsules” have recently re-emerged in the market. Many online stores and pharmacies have stated that the related products have been sold out, and some pharmacies that still have stock have only a few boxes left, but they have also increased their prices. It was sold out within a few days, and another pharmacy said that the manufacturer had no inventory, and it is expected that it will be replenished by the end of this month, but the price is expected to rise further.
The reporter inquired regarding several pharmacies yesterday. Among them, the staff of a pharmacy in Tuen Mun said that there are only 3 boxes left in the store. It was informed that the company that produced the proprietary Chinese medicine did not have enough stock in stock and might not return the goods in a short period of time.
Guangzhou Institute of Respiratory Health once pointed out that there are traditional Chinese medicines that play an important role and are trustworthy in the fight once morest the new crown epidemic. Among them, Lianhua Qingwen will have an inhibitory effect on the Delta new crown variant, and will also have a stable in vitro effect on Alpha, Beta and Delta. Antiviral effect, but the antiviral effect in vivo needs further study. The packaging instructions of “Lianhua Qingwen Capsules” indicate that the capsules contain honeysuckle, forsythia, Radix Isatidis, etc. Its functions are mainly for clearing and detoxifying, dispelling heat from the lungs, and treating heat toxins attacking the lungs, including fever, aversion to cold, and muscle soreness. , nasal congestion, runny nose, cough, headache, dry throat and sore throat.